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Abstract
MIER1a is a transcriptional regulator that functions in gene repression through its ability to interact with various chromatin
modifiers and transcription factors. We have also shown that MIER1a interacts with ERa and inhibits estrogen-stimulated
growth. While MIER1a is localized in the nucleus of MCF7 cells, previous studies have shown that it does not contain a
nuclear localization signal. In this report, we investigate the mechanism involved in transporting MIER1a into the nucleus.
We explored the possibility that MIER1a is transported into the nucleus through a ‘piggyback’ mechanism. One obvious
choice is via interaction with ERa, however we demonstrate that nuclear targeting of MIER1a does not require ERa.
Knockdown of ERa reduced protein expression to 22% of control, but did not alter the percentage of cells with nuclear
MIER1a (98% nuclear with scrambled shRNA vs. 95% with ERa shRNA). Further evidence was obtained using two stable
transfectants derived from the ER-negative MDA231 cell line: MC2 (ERa+) and VC5 (ERa-). Confocal analysis showed no
difference in MIER1a localization (86% nuclear in MC2 vs. 89% in VC5). These data demonstrate that ERa is not involved in
nuclear localization of MIER1a. To identify the critical MIER1a sequence, we performed a deletion analysis and determined
that the ELM2 domain was necessary and sufficient for nuclear localization. This domain binds HDAC1 & 2, therefore we
investigated their role. Confocal analysis of an MIER1a containing an ELM2 point mutation previously shown to abolish
HDAC binding revealed that this mutation results in almost complete loss of nuclear targeting: 10% nuclear vs. 97% with
WT-MIER1a. Moreover, double knockdown of HDAC1 and 2 caused a reduction in percent nuclear from 86% to 44%. The
results of this study demonstrate that nuclear targeting of MIER1a requires an intact ELM2 domain and is dependent on
interaction with HDAC1/2.
Citation: Li S, Paterno GD, Gillespie LL (2013) Nuclear Localization of the Transcriptional Regulator MIER1a Requires Interaction with HDAC1/2 in Breast Cancer
Cells. PLoS ONE 8(12): e84046. doi:10.1371/journal.pone.0084046
Editor: Alexander F. Palazzo, University of Toronto, Canada
Received September 20, 2013; Accepted November 20, 2013; Published December 20, 2013
Copyright:  2013 Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Canadian Institutes of Health Research FRN# MOP97938 (http://www.cihr-irsc.gc.ca); Canadian Breast Cancer Foundation (no grant number assigned)
(http://www.cbcf.org/atlantic). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: lgillesp@mun.ca
Introduction
MIER1 is a transcriptional regulator identified from a screen for
fibroblast growth factor (FGF) early response genes that are
activated during mesoderm induction in Xenopus laevis embryos [1].
MIER1 has been shown to repress transcription using several
distinct mechanisms, including recruitment of HDAC1 [2],
inhibition of the histone acetyltransferase activity of CBP [3]
and by displacement of Sp1 from its cognate site in the promoter
of target genes [4].
The mier1 gene is highly conserved among species [5,6] and
gives rise to multiple protein isoforms whose structure consists of a
common internal region with variable N- and C- termini [5]. The
common region contains four acidic stretches, an ELM2 domain
and a SANT domain, all of which play a role in transcriptional
regulation [1,2,4]. Two functional alternate N-termini have been
described: one that includes an additional exon (exon 3A)
encoding a bona fide nuclear export signal (NES; isoform is
designated MIER1-3A) [7] and one that does not (designated
MIER1). Two distinct C-termini, a and b, have also been
characterized. The a sequence contains a classic LXXLL motif for
interaction with nuclear receptors and indeed, MIER1a interacts
with ERa in breast carcinoma cells [8]. Moreover, regulated
overexpression of MIER1a was shown to inhibit estrogen-
stimulated growth in these cells [8]. Analysis of MIER1a protein
expression in patient biopsies revealed a dramatic shift in
subcellular localization, from nuclear to cytoplasmic during
progression to invasive breast carcinoma [8]. These data indicate
that nuclear MIER1a may play an important role in regulating
breast cancer growth and/or progression.
Understanding the mechanism(s) controlling subcellular local-
ization of the a isoform will be important for elucidating its role in
breast cancer. We showed previously that inclusion of exon 3A
altered the distribution in MCF7 cells, from nucleus to cytoplasm,
of the a but not the b isoform [7]. Thus, alternative splicing may
be sufficient to shuttle MIER1a out of the nucleus and regulate its
corepressor activity. Interestingly, deletion analysis has demon-
strated that the b C-terminus contains the only functional nuclear
localization signal (NLS) [9], leading to the question of how
MIER1a is transported to the nucleus. In this study, we show that
nuclear localization of MIER1a in breast carcinoma cells was not
through its association with ERa, as one might predict. Instead, it
transported to the nucleus through interaction with HDAC1/2.
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Materials and Methods
Cell lines and culture conditions
The human breast adenocarcinoma cell line, MCF7, was
obtained from the American Tissue Culture Collection (ATCC)
and cultured in DMEM (GIBCO) containing 10% serum (7.5%
calf serum (GIBCO) plus 2.5% fetal bovine serum (GIBCO)) and
1 mM sodium pyruvate (GIBCO). The MC2 and VC5 cell lines
were produced by Dr. V.C. Jordan (Georgetown University
Medical Center, Washington, DC) and derived by stably
transfecting the ER-negative MDA-MB-231 breast carcinoma cell
line with wild-type era or empty vector, respectively, as described
[10,11]. MC2 and VC5 cells were maintained in phenol red-free
MEM (GIBCO) containing 5% charcoal-dextran treated fetal
bovine serum (HyClone), 1% L-glutamine (GIBCO), 6 ng/ml
insulin (Invitrogen) and 200mg/ml Geneticin (Invitrogen). All cells
were grown a humidified 37uC incubator with 5% CO2.
Plasmids and Constructs
Human mier1 gene structure, the sequence of its transcripts and
the myc-tag vector (pCS3+MT; Dr David Turner, University of
Michigan; http://sitemaker.umich.edu/dlturner.vectors/cs2_poly
linker_descriptions) containing full-length mier1a have been
described in [5]. Myc-tagged MIER1a containing a point
mutation 213WRA in the ELM2 domain (ELM2 mutant) was
produced using the QuikChange site-directed mutagenesis kit
(Stratagene) and the following primers: 59-GAT CAG CTC CTG
GCG GAC CCT GAG TAC TTA CC-39 (forward); 59-GGT
AAG TAC TCA GGG TCC GCC AGG AGC TGA TC-39
(reverse). For the MIER1a deletion constructs, previously
described constructs containing amino acids (aa)1–283, aa163–
433, aa164–283, aa287–433, aa164–239, aa240–283, aa164–251
or aa164–273 of MIER1a in the Clontech pM vector [2] were
digested with EcoRI and the MIER1a insert was ligated into the
EcoRI site of a pCS3+MT vector that had been modified to
maintain the MIER1 sequence in-frame with the myc-tag. This
modified pCS3+MT, renamed pCS4+MT, contains a thymidine
(T) inserted upstream of the EcoRI site. All plasmids were
prepared using the NucleoBond Endotoxin-free Maxi Plasmid kit
(Clontech), according to the manufacturer’s instructions. The
sequences/mutations were confirmed by automated dideoxynu-
cleotide sequencing of both strands (DNA Sequencing Facility,
The Centre for Applied Genomics, The Hospital for Sick
Children, Toronto, Canada). Plasmids containing ERa shRNA,
HDAC1 shRNA, HDAC2 shRNA or a control scrambled shRNA
were purchased from Origene Technologies, Inc.
Figure 1. Knockdown of ERa does not affect nuclear localization of MIER1a in MCF7 cells. MCF7 cells were transfected with myc-tagged
MIER1a plus either a control, scrambled shRNA or an ERa shRNA and analyzed by confocal microscopy (A, B) or immunoblotting (C). (A) Illustrative
examples of cells showing stained nuclei (DAPI; panels a,e), MIER1a localization (9E10 anti-myc tag and an AlexaFluor-488 secondary antibody; panels
b, f) and ERa localization (HC-20 antibody and an AlexaFluor-647 secondary antibody; panels c, g). Panels d,h show merged 488 and 647 channels.
Arrowheads indicate nuclei. Note that MIER1a is nuclear even in cells that lack detectable ERa (arrowheads in panels f & g). (B) Histogram showing the
results of 3 independent experiments; random fields were selected and the staining pattern of each cell within the field was scored visually according
to the categories described in the RESULTS. 180-190 cells were scored for each shRNA. Plotted is the percentage of cells in each category6 S.D; there is
no significant difference between the percent nuclear for the two samples (p.0.05). (C) Western blot to confirm knockdown of ERa. Extracts from
MCF7 cells transfected with myc-tagged MIER1a and either empty vector (lane 1), control scrambled shRNA (lane 2) or ERa shRNA (lane 3). The blot
was stained with anti-b-actin (lower panel) to verify equal loading or with anti-ERa (upper panel).
doi:10.1371/journal.pone.0084046.g001
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Antibodies
The 9E10 anti-myc tag mouse monoclonal antibody was
prepared as described in Blackmore et al. [3]. The anti-ERa
antibody HC-20, anti-HDAC1 antibody H-51 and anti-HDAC2
antibody H-54 were purchased from Santa Cruz Biotechnology
Inc. For confocal analysis, Alexa Fluor-488 labeled donkey anti-
mouse and Alexa Fluor-647 labeled donkey anti-rabbit were
purchased from Jackson ImmunoResearch Laboratories, Inc.
HRP-labeled sheep anti-mouse and donkey anti-rabbit antibodies
were purchased from GE Healthcare Corp. Anti-b-actin (A5441)
was purchased from Sigma-Aldrich Co.
Transient Transfection
Cells were transfected by electroporation using the NeonH
electroporation device (Invitrogen Corp.) and the following
settings: 1000 V, 30 ms, 2 pulses for MCF7 or 1400 V, 10 ms, 4
pulses for MC2 and VC5. 36105 (MCF7) or 2.66105 (MC2 and
VC5) cells were mixed with 0.5 mg myc-tagged plasmid and
loaded into a 10 cl tip for electroporation. For the ERa shRNA
knockdown experiments, 1.0mg shRNA and 0.5mg myc-tagged
plasmid were mixed together with 36105 MCF7 cells, and then
loaded into a 10ml tip for electroporation. After transfection, cells
were plated at a density of 46104/well in Falcon 8-well culture
slides (BD BioSciences) for confocal analysis or 36105/well in 6-
well dish for Western blot analysis. For the HDAC1 and 2 double
knockdown experiments, 0.8mg of each HDAC shRNA plasmid
was used for electroporation; for single knockdowns, the total
amount of plasmid transfected was kept constant by adding 0.8mg
of scrambled shRNA plasmid. Electroporation and plating was
performed as above. Sixteen hours after electroporation, cells were
transfected with 0.5mg plasmid encoding myc-tagged MIER1a
using Mirus TransIT-LT1 transfection reagent (Medicorp, Inc.) in
a 3:1 ratio of reagent:DNA (v/w), according to the manufacturers’
protocol. Transfected cells were cultured for a total of 48 h, then
either fixed with 4% paraformaldehyde/PBS for confocal analysis,
or solubilized in 400ml of SDS sample buffer (50 mM Tris-Cl
pH6.8, 2% SDS, 5% b-mercaptoethanol, 10% glycerol, 0.1%
bromophenol blue) for Western analysis.
Figure 2. MIER1a is localized in the nucleus in ER- breast carcinoma cells. MDA231-derived cell lines, VC5 (vector) and MC2 (stably
expressing ERa), were transfected with myc-tagged MIER1a and analyzed by confocal microscopy using DAPI (a, e), 9E10 anti-myc tag (b,f), anti-ERa
(c,g) and the secondary antibodies described in the legend to Fig. 1. Panel d shows merged MIER1a and DAPI staining while panel h shows merged
MIER1a and ERa staining. Note that MIER1a is localized in the nucleus in VC5 cells, even in the absence of ERa (arrowheads in panels a-d). (B)
Histogram showing the results of 3 independent experiments; random fields were selected and the staining pattern of each cell within the field was
scored visually. 170-380 cells were scored for each cell line. Plotted is the percentage of cells in each category 6 S.D; there is no significant difference
between the percent nuclear for the two cell lines (p.0.05).
doi:10.1371/journal.pone.0084046.g002
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Figure 3. The ELM2 domain is sufficient for nuclear localization of MIER1a. MCF7 cells were transfected with myc-tag empty vector (panels
a-c), myc-tagged full-length MIER1a (d-f) or a myc-tagged MIER1a deletion construct containing either the acidic + ELM2 domains (g-i), the ELM2 +
SANT + a C-terminus (j-l), the SANT domain + a C-terminus (m-o) or the ELM2 domain alone (p-r). Localization was analyzed by confocal microscopy
using DAPI and 9E10 anti-myc tag antibody. (A) Illustrative examples of cells showing stained nuclei and MIER1a localization; arrowheads show
examples of nuclei. A schematic, drawn to scale and illustrating the MIER1a domains and constructs used, is shown on the right; the acidic stretches
are shown as black bars, the ELM2 domain is in yellow, the SANT domain in purple, the a C-terminus in pink and all remaining sequence in blue. The
amino acids (aa) encoded by each construct are indicated. The myc epitope tag is shown in green. (B) Histogram showing the results of 3
independent experiments; random fields were selected and the staining pattern of each cell within the field was scored visually. 220–970 cells were
scored for each construct. Plotted is the percentage of cells in each category 6 S.D; the percent nuclear for the SANT domain + a C-terminus (aa287-
433) construct is significantly less than that for full-length MIER1a (p,0.05). (C) Bar graph showing the intracellular distribution of MIER1a. Pixel
MIER1a Translocates to the Nucleus by Binding HDAC
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Immunofluorescence, Confocal Microscopy and Analysis
Cells were fixed for 10 min with 4% paraformaldehyde and
permeabilized with 0.1% Triton X-100/PBS for 5 min. Non-
specific sites were blocked with 5% donkey serum in PBS for 1 h
before overnight incubation with primary antibodies (1:200
dilution) at 4uC. Subsequently, the cells were incubated with
Alexa Fluor-488 labeled donkey anti-mouse secondary antibody
(1:200) and/or with Alexa Fluor-647 labeled donkey-anti-rabbit
(1:200) for 1 h at RT. Nuclei were counterstained with 2.5mg/ml
49, 6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich Co.) for
1 h. All slides were mounted in 10% glycerol/PBS. Cells were
examined under an Olympus FluoView FV1000 confocal
microscope. Fluorescence images were obtained by sequential z-
stage scanning in two or three channels (DAPI, Alexa Fluor-488
and/or Alexa Fluor-647); z-stacks were compiled into individual
images.
Quantitative analysis of confocal z-stacks was performed using
Image J software v1.48 [12], as described in [7]. Briefly, cell
outlines were traced and the sum of the pixel values within the
outlines for all slices was determined. After subtracting the
background, this value was used as the corrected whole cell
MIER1 fluorescence. The sum of the pixel values for nuclei was
determined in the same way and used as corrected nuclear MIER1
fluorescence. The nuclear value was subtracted from the whole cell
value to obtain cytoplasmic MIER1 fluorescence and the
corrected fluorescence value in each compartment was plotted as
a proportion of the total. 20-30 cells were measured for each
sample.
Statistical analysis was performed using a two-sided Fisher’s
exact test with the Instat v3.0 software program (Graphpad
Software, San Diego, CA, USA).
Co-immunoprecipitation (co-IP) and Western Blot
Analysis
Forty-eight hours post-transfection (described above), cells were
washed once with 1xPBS and lysed on ice for 30 min in 1xIP
buffer (1% Triton X-100, 150 mM NaCl, 10 mM Tris-Cl pH7.4,
10 mM EDTA, 0.02% Sodium Azide, 1 mM PMSF, 1% protease
inhibitor cocktail). Cell lysates were passed several times through a
26-gauge needle then centrifuged at 12,0006g for 15 min at 4uC.
The supernatants were incubated overnight at 4uC with anti-
HDAC1 or anti-HDAC2 antibody pre-bound to Protein A-
agarose beads (Pierce Biotechnology). After incubation, the beads
were washed six times with ice-cold 1xIP buffer and bound
proteins were solubilized in 30ml of 1.5x SDS sample buffer and
analyzed by SDS-PAGE-Western.
Western blot analysis was performed as in [13] using 7% SDS-
PAGE gels. Transfers were performed using 0.2mm PVDF
membranes (Trans-Blot TurboTM Transfer Pack; Bio-Rad) and
the Trans-Blot Turbo
TM
system (Bio-Rad) set at 1.3A, 25 V for
7 min. Membranes were stained using a 1:1000 dilution of
primary antibody, 1:3000 HRP-labeled secondary antibody and
Amersham’s ECL Plus Western Blotting System (GE Healthcare
Corp.). Quantitative analysis of the ERa, HDAC1 and HDAC2
protein bands was performed using Image J software v1.48 [12].
Results
Nuclear localization of MIER1a is not dependent on its
interaction with ERa
In our original characterization of human MIER1a and
MIER1b, we determined that the a isoform localized in the
cytoplasm of NIH3T3 cells, while the b isoform was exclusively
nuclear [14]. Subsequently, deletion analysis confirmed that
MIER1a does not contain a functional NLS [9] and yet it is
localized in the nucleus of MCF7 breast carcinoma cells [7]. Given
that MIER1a interacts with ERa [8], we investigated whether
MIER1a is carried into the nucleus of MCF7 cells by binding to
ERa, in a ‘piggyback’ fashion. Cells were transfected with plasmids
encoding a myc-tagged MIER1a along with either an ERa
shRNA or a scrambled, control shRNA and localization was
determined by confocal microscopy. Subcellular localization was
scored as: 1) NUCLEAR; if the nucleus was intensely stained, with
little or no cytoplasmic staining; 2) CYTOPLASMIC; if staining was
primarily in the cytoplasm, with little or no staining in the nucleus;
3) WHOLE CELL; if both the nucleus and cytoplasm were stained.
The shRNA was effective at knocking down endogenous ERa
expression levels, as determined by Western blot and confocal
microscopy, while the scrambled shRNA had no effect (Fig. 1A,
compare panels c & g; Fig. 1C, compare lanes 2 & 3). ImageJ
analysis of the Western blot in Fig. 1C, determined that ERa
expression was knocked down to 22% of control. In cells
expressing the scrambled shRNA, 98% displayed nuclear
MIER1a (Fig. 1A panels a-d, &1B) and this pattern did not
change when ERa expression was knocked down. 95% of cells
expressing ERa shRNA displayed nuclear MIER1a (Fig. 1A
panels e-h, &1B), even cells with no detectable ERa (see
arrowheads in Fig. 1A, panels f & g).
To confirm that ERa is not required for targeting MIER1a to
the nucleus, we examined localization in two clonal lines of MDA-
MB-231 (ER-), MC2 and VC5, stably expressing ERa or empty
vector, respectively [10,11]. MC2 and VC5 cells were transfected
with myc-tagged MIER1a and localization was determined by
confocal microscopy (Fig. 2). Similar localization patterns were
seen in the 2 cell lines: most cells exhibited nuclear MIER1a
(Fig. 2B; 89% for VC5 and 86% for MC2), regardless of whether
ERa was present (Fig. 2A, panels b-c & f-g). Taken together, these
data demonstrate that ERa is not involved in transporting
MIER1a to the nucleus.
The ELM2 domain of MIER1a is required and sufficient for
targeting to the nucleus
Identifying the region of MIER1a that is required for nuclear
targeting might provide insight into the mechanism involved.
Therefore, we performed a deletion analysis of myc-tagged
MIER1a. MCF7 cells were transfected with plasmids encoding
full-length MIER1a (aa1-433) or with a deletion construct
containing the following regions: 1) the N-terminal acidic stretches
+ the ELM2 domain (aa1-283), 2) the ELM2 + SANT + a C-
terminus (aa164-433), 3) the SANT + a C-terminus (aa287-433) or
4) the ELM2 domain alone (aa164-283) (Fig. 3). Localization was
determined by confocal microscopy and compared to the myc-tag
alone and to full-length MIER1a. The myc-tag alone displays
whole cell staining (Fig. 3A, panels a-c; Fig. 3B), as expected of a
macromolecule that is sufficiently small (,40 kDa) to undergo
values for the nuclear and the cytoplasmic compartments were measured in confocal z-stacks using Image J v1.38; plotted is the proportion of the
total signal in each compartment, using measurements from 20–30 cells for each construct. The proportion of the SANT domain + a C-terminus
(aa287-433) construct in the nuclear compartment is significantly less than that of full-length MIER1a (p,0.05).
doi:10.1371/journal.pone.0084046.g003
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Figure 4. Nuclear localization requires an intact ELM2 domain. MCF7 cells were transfected with a myc-tagged intact ELM2 domain (aa164–
283) (panels a-c) or a myc-tagged ELM2 deletion construct containing aa164-239 (panels d-f), aa240-283 (panels g-i), aa164-251 (panels j-l), aa164-273
MIER1a Translocates to the Nucleus by Binding HDAC
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passive diffusion through the nuclear pore (reviewed in [15]). Myc-
tagged full-length MIER1a, on the other hand, is almost
exclusively nuclear (97%; Fig. 3A, panels d-f; Fig. 3B-C).
Constructs 1 & 2 localized in the nucleus, similar to full-length
MIER1a (94% and 98% nuclear; Fig. 3A, panels g-l; Fig. 3B-C),
while construct 3 showed a distribution pattern similar to the myc
tag alone, i.e. whole cell (0% nuclear; Fig. 3A, panels m-o; Fig. 3B-
C). Thus, only constructs containing the ELM2 domain were
targeted to the nucleus and indeed, the ELM2 domain in isolation
was localized in the nucleus (85% nuclear; Fig. 3A, panels p-r, &
Fig. 3B-C). To obtain a quantitative measure of MIER1a
localization within the cell, we performed an analysis of confocal
z-stacks for each construct, using the ImageJ software program
[12] and determined the fluorescence in the nuclear and
cytoplasmic compartments (Fig. 3C). The results of this analysis
show that 93% of full-length MIER1a and 83–84% of constructs
1, 2 & 4 are in the nuclear compartment, while only 37% of
construct 3 was nuclear. Together these results demonstrate that
the ELM2 domain is necessary and sufficient to target MIER1a to
the nucleus.
To further define the sequence required for nuclear targeting,
we produced 4 myc-tagged deletion constructs of the ELM2
domain for analysis. The first two were designed to divide the
120aa ELM2 domain into an N-terminal 76aa and a C-terminal
44aa portion (Fig. 4A, panels d-i). In contrast to the intact ELM2
construct (Fig. 4A, panels a-c, & Fig. 4B), neither portion was
targeted to the nucleus (Fig. 4A, panels d-i, & Fig. 4B). To verify
that the critical sequence was not bisected in these 2 constructs, we
produced 2 additional constructs that maintained the integrity of
this region. C-terminal deletions were designed to remove either
the last 10aa or the last 32aa. As can be seen in Fig. 4A, panels j-o,
& Fig. 4B, neither construct was localized in the nucleus. Thus,
removal of as little as 10aa from the C-terminus of the ELM2
domain abolished nuclear targeting. These data lead us to
conclude that an intact ELM2 domain is required for nuclear
targeting of MIER1a.
Interaction with HDAC1/2 is required for nuclear
localization of MIER1a
The results presented in Figure 4 are reminiscent of a previous
study characterizing the interaction of MIER1a with HDAC1 [2].
Utilizing a similar deletion analysis, this interaction was shown to
require an intact ELM2 domain. In fact a single point mutation of
a highly conserved tryptophan (W) at position 213 in the ELM2
domain abolished interaction between MIER1 and HDAC1.
MIER1 also interacts with the highly related HDAC2, but not
with any of the other class I, IIa, IIb or IV HDACs [16,17] and
HDAC1/2 are the only proteins known to interact with the ELM2
domain of MIER1a. Therefore, we investigated whether interac-
tion with HDAC1/2 plays a role in nuclear localization of
MIER1a. MCF7 cells were transfected with either a myc-tagged,
full-length wild-type MIER1a (WT-MIER1a) or a myc-tagged
full-length mutant containing the point mutation 213WRA (ELM2
mutant) and analyzed by co-IP for interaction with endogenous
HDAC1 or HDAC2. Subcellular localization was determined by
confocal microscopy in parallel samples. Our co-IP results confirm
WT-MIER1a interaction with both HDAC1 and HDAC2
(Fig. 5C, lane 2, upper and lower panels) and demonstrate that
the ELM2 mutant does not interact with either HDAC1 or
HDAC2 (Fig. 5C, lane 3, upper and lower panels). Confocal
analysis revealed that HDAC1 and 2 expression levels were not
affected by expression of the ELM2 mutant (Fig. 5A&B, compare
panels b and f); however nuclear targeting is lost with this ELM2
point mutation (Fig. 5A&B, compare panels c and g; Fig. 5D), with
only 10% of cells now showing nuclear staining. Quantitative
analysis of the fluorescence in the nuclear and cytoplasmic
compartments using ImageJ shows that 90% of wild-type MIER1a
is in the nucleus but that there was significantly less (44%) of the
ELM2 mutant located in the nuclear compartment (Fig. 5E;
p,0.05). These data suggest that interaction with HDAC1/2 is
required to target MIER1a to the nucleus.
To confirm the role of HDAC1/2 in nuclear localization of
MIER1a, we investigated the effect of depleting HDAC1 and 2
using shRNA. MCF7 cells were co-transfected with a plasmid
encoding a myc-tagged MIER1a along with either a control
shRNA, an HDAC1 shRNA, an HDAC2 shRNA or both
HDAC1&2 shRNAs. Localization was determined by confocal
microscopy and quantified by ImageJ analysis of confocal z-stacks
(Fig. 6C–E); HDAC1 and 2 knockdown was verified in parallel
samples by Western Blot (Fig. 6A–B). Individual knockdowns of
HDAC1 and HDAC2 help confirm that each shRNAs used in this
analysis is specific for its target and allow us to determine the
requirement of each for nuclear localization of MIER1a. HDAC1
shRNA was effective in knocking down endogenous HDAC1 to
27% of control while having little effect on HDAC2 expression
(Fig. 6A, lanes 2 & 6; Fig. 6B). Likewise, HDAC2 shRNA reduced
endogenous HDAC2 levels to 45% of control without affecting
HDAC1 (Fig. 6A, lanes 7 & 3; Fig. 6B). In cells transfected with
both shRNAs, HDAC1 and 2 were reduced to 26% and 44%,
respectively (Fig. 6A, lanes 4 & 8; Fig. 6B). These data confirm the
specificity and effectiveness of the shRNAs used in this set of
experiments.
Confocal analysis of cells depleted for HDAC1, HDAC2 or for
both revealed a significant reduction in the percentage of cells with
nuclear MIER1a when compared to controls (p,0.05; Fig. 6C
and 6E, compare panels b&f). Exclusively nuclear MIER1a was
detected in 86% of control cells, but reduced to 58% of those
depleted for HDAC1, 51% of those depleted for HDAC2 and
44% of those depleted for both (Fig. 6C). Quantitative analysis of
confocal z-stacks revealed a similar pattern: in the control, 88% of
MIER1a was in the nuclear compartment and this was reduced to
59%, 55% and 52% in HDAC1, HDAC2 and HDAC1&2
depleted cells, respectively (Fig. 6D). These data confirm that
depletion of HDAC1 or HDAC2 or both results in a significant
reduction of MIER1a in the nucleus (p,0.05). Together, these
results demonstrate that both HDACs are involved in targeting
MIER1a to the nucleus.
(panels m-o). Localization was analyzed by confocal microscopy using DAPI and the 9E10 anti-myc tag antibody. (A) Illustrative examples of stained
cells showing MIER1a localization. Note that nuclear localization was only detected with an intact ELM2 domain (a-c); arrowheads indicate examples
of stained nuclei. The rest of constructs displayed whole cell staining (arrows in d-o). A schematic, drawn to scale and illustrating the constructs used,
is shown on the right as are the amino acids (aa) encoded by each construct. The myc epitope tag is shown in green. (B) Histogram showing the
results of 3 independent experiments; random fields were selected and the staining pattern of each cell within the field was scored visually. 465-565
cells were scored for each construct. Plotted is the percentage of cells in each category 6 S.D; the percent nuclear of all deletion constructs are
significantly less than that of the intact ELM2 domain (p,0.05).
doi:10.1371/journal.pone.0084046.g004
MIER1a Translocates to the Nucleus by Binding HDAC
PLOS ONE | www.plosone.org 7 December 2013 | Volume 8 | Issue 12 | e84046
Figure 5. Interaction with HDAC1/2 is required for nuclear localization of MIER1a. MCF7 cells were transfected with myc-tagged, full-
length, wild-type MIER1a (a-d) or a full-length, mutant MIER1a (e-h) containing a single point mutation (213WRA) in the ELM2 domain (ELM2 mutant)
known to abrogate its ability to interact with HDAC1/2. Localization was analyzed by confocal microscopy using DAPI, 9E10 anti-myc tag (AlexaFluor-
488) and anti-HDAC1 (panel A) or anti-HDAC2 (panel B) (AlexaFluor-647). (A-B) Illustrative examples of cells showing HDAC and MIER1a localization.
Note that the ELM2 mutant loses the exclusively nuclear staining seen with wild-type MIER1a (arrowheads in c) and shows predominantly whole cell
staining (arrows in g). (C) Western blot showing that the ELM2 mutant does not interact with HDAC1 or HDAC2. MCF7 cells were transfected myc-tag
empty vector (lane 1, 6), myc-tagged full-length wild-type MIER1a (lanes 2, 4) or myc-tagged full-length ELM2 mutant (lanes 3, 5). Cell extracts were
either subjected to immunoprecipitation (lanes 1–3) with anti-HDAC1 (upper panel) or anti-HDAC2 (lower panel) or loaded directly on the gel (lanes
4–6). Blots were stained with the 9E10 anti-myc tag antibody. (D) Histogram showing the results of 3 independent experiments; random fields were
selected and the staining pattern of each cell within the field was scored visually;.275 cells were scored for each construct. Plotted is the percentage
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of cells in each category 6 S.D; the percent nuclear for the ELM2 mutant is significantly less than that of wild-type MIER1a (p,0.05). (E) Bar graph
showing the intracellular distribution of MIER1a. Pixel values for the nuclear and the cytoplasmic compartments were measured in confocal z-stacks
using Image J v1.38; plotted is the proportion of the total signal in each compartment, using measurements from 30 cells for each construct. The
proportion of the ELM2 mutant in the nucleus is significantly less than that of WT-MIER1a (p,0.05).
doi:10.1371/journal.pone.0084046.g005
Figure 6. HDAC1 and 2 knockdown reduces nuclear localization of MIER1a. MCF7 cells were transfected with myc-tagged MIER1a and
either control shRNA or HDAC shRNA(s), then analyzed by immunoblotting (A–B) or confocal microscopy (C–E). (A–B) Western blot analysis to confirm
HDAC knockdown and specificity of each shRNA. Extracts from MCF7 cells were transfected with myc-tagged MIER1a and either control scrambled
shRNA (Con; lane 1, 5), HDAC1 shRNA (Hd1; lane 2, 6), HDAC2 shRNA (Hd2; lane 3, 7) or both HDAC1 and 2 shRNAs (Hd1+Hd2; lanes 4, 8). Duplicate
samples were stained with anti-HDAC1 (lanes 1–4) or anti-HDAC2 (lanes 5–8). The blots were restained with anti-b-actin (lower panels) to verify equal
loading. (B) The HDAC protein bands shown in (A) were quantified using ImageJ, normalized to b-actin and plotted as a proportion of the HDAC level
in control cells. Note that each shRNA is specific for its target. (C) Localization was analyzed in parallel samples by confocal microscopy. Histogram
showing the results of 2 independent experiments; random fields were selected and the staining pattern of each cell within the field was scored
visually; 400–600 cells were scored for each shRNA. Plotted are the percentage of cells in each category6 S.D; the percent nuclear of HDAC1, HDAC2
or HDAC1&2 depleted cells were significantly less than that of controls (p,0.05). (D) Bar graph showing the intracellular distribution of MIER1a. Pixel
values for the nuclear and the cytoplasmic compartments were measured in confocal z-stacks using Image J v1.38; plotted is the proportion of the
total signal in each compartment, using measurements from 20–25 cells for each shRNA. The proportion of MIER1a in the nucleus is significantly less
in depleted cells than in controls (p,0.05 for each). (E) Illustrative examples of cells depleted for both HDAC1 and 2, stained as described in the
legend to Fig. 5 for MIER1a (panels b, f) and with combined anti-HDAC1 and 2 antibodies (panels c, g), using MCF7 cells co-transfected with myc-
tagged MIER1a and either control shRNA (panels a-d) or HDAC1 + HDAC2 shRNAs (panels e-h). Note that MIER1a staining is nuclear in control cells
(arrowheads in a–d) but predominantly ‘whole cell’ in cells with reduced HDAC1&2 staining (arrowheads in e–h).
doi:10.1371/journal.pone.0084046.g006
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Discussion
Although small proteins can passively diffuse through the
nuclear pore, the majority of proteins with nuclear functions
undergo active transport into the nucleus (reviewed in [18]). The
most common transport mechanism involves recognition of a
classic NLS within the cargo protein by the importins, which then
mediate interaction with the nuclear pore complex (NPC) and
translocation into the nucleus. However, other mechanisms have
been described, including direct binding to nucleoporins in the
NPC, e.g. b-catenin [19], piggyback through interaction with
another nuclear protein, e.g. LEF-1 [20], BRCA1 (reviewed in
[21]) or calmodulin-mediated nuclear import, e.g. Sox-9 [22].
Therefore, it is not surprising that MIER1a can be localized in the
nucleus even though it does not contain a recognizable, functional
NLS. However, it was unexpected to discover that even though
MIER1a binds ERa and inhibits its growth stimulating activity,
this interaction is not involved in transporting MIER1a to the
nucleus. This leads us to conclude that MIER1a only interacts
with ERa once it is in the nucleus.
HDAC1 and 2 are widely expressed [23,24] and frequently
located together in three major multiprotein corepressor com-
plexes: Sin3, NuRD, and CoREST [17,25,26]. Interestingly,
MIER1 is not contained in any of these complexes, but rather
forms part of a unique corepressor complex with HDAC1&2,
CDYL and G9a [16,17]. HDAC1 and HDAC2 are nearly
identical [26,27], with an overall sequence identity of 82% and
both belong to the class I HDACs along with HDAC3 and 8
(reviewed in [24]). They contain a C-terminal NLS and, unlike
other classes, members of this class are found almost exclusively in
the nucleus. HDAC1 can associate with itself as well as
heterodimerize with HDAC2 and this interaction is mediated
through an N-terminal region that includes part of the conserved
HDAC domains [24]. While HDAC’s primary role is in chromatin
remodeling, HDAC2 has been shown to interact with the
endosomal protein APPL1 and contribute to its nuclear localiza-
tion [28]. Our results provide additional evidence that HDACs
can play a role in nuclear localization.
Our data show that depletion of either HDAC1 or HDAC2
reduces nuclear localization of MIER1a, demonstrating that both
are involved in this process. It was interesting to note that the
reduction in nuclear localization was similar whether HDAC1 or 2
or both were knocked down. This combined with the fact that 80–
90% of HDAC1 and 2 exist as heterodimers in MCF7 cells [29],
suggests that it is the heterodimer that is required for targeting
MIER1a to the nucleus.
In a recent report, we showed that alternative splicing of
MIER1a to include an additional exon encoding a functional NES
resulted in shuttling of this a isoform to the cytoplasm [7]. Thus
RNA splicing may represent a primary mechanism for regulating
the nucleo-cytoplasmic distribution of the a isoform. However, we
cannot rule out the possibility that the MIER1a isoform is also
shuttled out of the nucleus through interaction with a NES-
containing protein. MIER1a has been shown to interact several
molecules in addition to ERa [8] and HDAC1/2 [2]; these include
the histone methyltransferase G9a [30], the chromodomain-
containing protein CDYL [31] and the histone acetyltransferase
CBP [3]. However, none of these has been reported to contain a
NES.
Current evidence suggests that MIER1a functions as a tumour
suppressor [8], possibly through its interaction with ERa. Our
previous analysis of normal breast tissue and breast cancer
tumours using an antibody that specifically recognizes the a C-
terminus, showed that the a isoform(s) is localized in the nucleus in
normal tissue and in hyperplasia, however the percentage of cells
with nuclear staining decreased to 50% in DCIS and to 4% in
IDC [8]. This suggests that loss of nuclear MIER1a might
represent a critical event in breast cancer progression since
shuttling to the cytoplasm would interfere with its nuclear function
as a transcriptional repressor. It is also possible that MIER1a has
additional, as yet undescribed, activity in the cytoplasm. Several
instances of dual roles have been reported for other transcriptional
regulators (reviewed in [32,33]). For example, ERa functions in
the nucleus to regulate transcription of target genes but also has
non-genomic functions (reviewed in [34]). Most of these involve
activation of various signaling cascades in a tissue-specific manner,
including activation of ERK, PI3’K and Akt pathways as well as
signaling through GPCR and growth factor receptors. Whether or
not MIER1a also has non-genomic functions awaits further
investigation.
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